5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity

BackgroundDigoxin is a high-alert medication because of its narrow therapeutic range and high drug-to-drug interactions. Fifty per cent of cases of digoxin toxicity can be prevented by improving treatment with digoxin.PurposeChecking whether the dosage of digoxin in intoxicated patients accords with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A212-A212
Hauptverfasser: Martínez Simón, JJ, Martín Suárez, A, Gómez Pedrero, AM, Pérez Encinas, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundDigoxin is a high-alert medication because of its narrow therapeutic range and high drug-to-drug interactions. Fifty per cent of cases of digoxin toxicity can be prevented by improving treatment with digoxin.PurposeChecking whether the dosage of digoxin in intoxicated patients accords with clinical guidelines’ recommendations.Material and methodsRetrospective study of patients discharged fbetween 2015–2017, presented as a primary or secondary diagnosis of digitalis toxicity. Variables: date of birth, sex, weight, size, diagnosis for treatment with digoxin – atrial fibrillation (AF) or heart failure (HF) – daily dose of digoxin, serum creatinine, digoxinemia and Potasemia (K +). It was estimated whether the dosage of digoxin was correct based on anthropometric data and doses of daily digoxin using PKS. For those inadequately dosed patients, daily doses of adequate digoxin were calculated. The glomerular filtration rate (GFR) was calculated by MDR/CKD-EPI.ResultsSixty-four patients (47 females), median age: 83.7 years (55–102), median weight: 69.2 kg (45.5–10 5 kg) with 52% below 70 kg were considered in the dosage recommendations. The mean value of GFR 50, 65 mL/min (SD=19.9) (77%
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.456